CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
November 2017—Rosetta Genomics entered into a definitive agreement in early September to sell all of its ownership interest in PersonalizeDx to Pragmin Prognosis. PDx is a molecular diagnostics and services company serving community-based pathologists, urologists, and oncologists with tests for various cancers including bladder, prostate, lung, breast, and hematological malignancies offered through a CLIA laboratory based in Lake Forest, Calif.
The purchase price is $2.875 million in cash with $1.25 million to be paid at closing.
Rosetta Genomics, 877-429-6643